LOGO
LOGO

NRx Pharma To Report Suicidal Bipolar Depression Trial Results This Month

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
rttnewslogo20mar2024

It is estimated that every 27 seconds, someone in the U.S. attempts suicide. The risk of Acute Suicidal Ideation and Behavior, or ASIB, is uniquely high in patients during bipolar depressive episodes, compared to those with major depressive disorder, thought disorders, and personality disorders. Between 11% to 20% of individuals diagnosed with bipolar disorder will ultimately succumb to suicide, according to reports.

The stock we are bringing to your attention today is that of NRx Pharmaceuticals Inc. (NRXP), which is developing a drug for suicidal treatment-resistant bipolar depression.

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update - Jun 01 - Jun 05, 2026

June 05, 2026 16:18 ET
A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.

Latest Updates on COVID-19